CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical-stage biotechnology company developing novel CXCR4 allosteric antagonist drug candidates designed to improve immune cell trafficking to treat rare diseases and cancer, has been selected to present data on X4P-001-IO, a CXCR4 antagonist, at two upcoming oncology medical meetings. The company will present clinical data on X4P-001-IO in advanced renal cell carcinoma (RCC) in a Poster Discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place October 19-23 in Munich. X4 will also present clinical data on X4P-001-IO in melanoma at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 9-11 in Washington DC.
Details of the presentations on X4P-001-IO are as follows:
|
European Society for Medical Oncology (ESMO) |
|||||||
|
Title: |
A Phase 1a/2b Trial of the CXCR4 Inhibitor X4P-001 and Nivolumab for Advanced Renal Cell Carcinoma (RCC) that is Unresponsive to Nivolumab Monotherapy |
||||||
|
|
|
||||||
|
Session Type: |
Poster Discussion session – Immunotherapy of Cancer 1 |
||||||
|
Date & Time: |
Oct. 20, 2018, 4:45 - 5:45 p.m. CET |
||||||
|
Location: |
ICM - Room 14b |
||||||
|
Presentation #: |
1134PD |
||||||
|
Poster Display: |
Designated Poster Discussion area in Hall B4, displayed for the duration of the Congress |
||||||
|
Society for Immunotherapy of Cancer (SITC) |
|||||||
|
Title: |
X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma |
||||||
|
Session Type: |
Poster session | ||||||
|
Date & Time: |
Friday, Nov. 9, from 8 a.m. – 8 p.m. ET | ||||||
|
Saturday, Nov. 10, from 8 a.m. – 8:30 p.m. ET |
|||||||
|
Location: |
Hall E | ||||||
|
Poster #: |
P53 | ||||||
About X4P-001-IO in Cancer
X4P-001-IO is an investigational selective, oral, small molecule antagonist of C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in abundance on certain immune cells and cancer cells and it plays a critical role in immune cell trafficking, infiltration and activation in the tumor microenvironment. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO has the ability to help restore immunity within the tumor microenvironment and has the potential to enhance the anti-tumor activity of approved and emerging oncology agents, such as checkpoint inhibitors and targeted therapies. X4P-001-IO is being investigated in several clinical studies in solid tumors.
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease and is currently under investigation in multiple clinical trials in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit www.x4pharma.com.
